The discoveries of EGFR mutations and ALK rearrangements as actionable oncogenic
drivers in non-small-cell lung cancer (NSCLC) has propelled a biomarker-directed treatment …

Anaplastic lymphoma kinase (ALK) is a potent oncogenic driver in lung cancer. ALK tyrosine
kinase inhibitors yield significant benefit in patients with ALK fusion-positive (ALK+) lung …

The expanding spectrum of both established and candidate oncogenic driver mutations
identified in non-small-cell lung cancer (NSCLC), coupled with the increasing number of …

By hijacking endogenous E3 ligase to degrade protein targets via the ubiquitin-proteasome
system, PROTACs (PRoteolysis TArgeting Chimeras) provide a new strategy to inhibit …

Receptor tyrosine kinases (RTKs) play an important role in a variety of cellular processes
including growth, motility, differentiation, and metabolism. As such, dysregulation of RTK …

Anaplastic lymphoma kinase (ALK) is a validated molecular target in several ALK-
rearranged malignancies, including non–small cell lung cancer. However, the clinical …

Purpose Fusions involving the ALK gene are the predominant genetic lesion underlying
pediatric anaplastic large cell lymphomas (ALCL) and inflammatory myofibroblastic tumors …

In the past two decades, several molecular targeted inhibitors have been developed and
evaluated clinically to improve the survival of patients with cancer. Molecular targeted …

Vaccination was first pioneered in the 18th century by Edward Jenner and eventually led to
the development of the smallpox vaccine and subsequently the eradication of smallpox. The …

Chromosomal rearrangements have a central role in the pathogenesis of human cancers
and often result in the expression of therapeutically actionable gene fusions. A recently …